Renin inhibition: A new modality for hypertension management

Current Hypertension Reports

Volumn 9, Issue 4, 2007, Pages 291-294

  Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; REMIKIREN; RENIN; RENIN INHIBITOR; VALSARTAN; ZANKIREN;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDICAL RESEARCH; MONOTHERAPY; NONHUMAN; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPECIES DIFFERENCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 34548509212     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0053-z     Document Type: Review

References (21)

1. Derkx FHM, Tan-Tjiong HL, Man in't Veld AJ, et al.: Activation of inactive plasma renin by plasma and tissue kallikreins. Clin Sci (Lond) 1979, 57:351-357.
2. Danser AHJ, van den Dorpel MA, Deinum J, et al.: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989, 68:160-167.
3. Alderman MH, Madhavan S, Ooi WL, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098-104.
4. Michel JB, Guettier C, Philippe M, et al.: Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 1987, 84:4346-4350.
5. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002, 39:e1-e8.
6. de Gasparo M, Cumin F, Nussberger J, et al.: Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol 1989, 27:587-596.
7. Rongen GA, Lenders JWM, Smits P, Thien T: Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 1995, 29:6-14.
8. Kleinbloesem CH, Weber C, Fahrner E et al.: Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther 1993, 53:585-592.
9. Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
10. Wood JM, Schnell CR, Cumin F, et al.: Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005, 23:417-426.
11. Eder J, Hommel U, Cumin F, et al.: Aspartic proteases in drug discovery. Curr Pharm Des 2007, 13:271-285.
12. Dieterle W, Corynen S, Mann J: Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004, 58:433-436.
13. Pilz B, Shagdarsuren E, Wellner M, et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005, 46:569-576.
14. Stanton A, Jensen C, Nussberger J, O'Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137-1143.
15. Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
16. Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226.
17. O'Brien E, Barton J, Nussberger J, et al.: Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007, 49:276-284.
18. Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. Am Soc Nephro12004, 15:3126-3133.
19. Pool JL, Schmieder RE, Azizi M, et al.: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007, 20:11-20.
20. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055.
21. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet 2006, 368:1449-1456.